Literature DB >> 26067223

Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort.

Xiaopeng Yan1, Xu Fu, Chuang Cai, Xuejian Zi, Hui Yao, Yudong Qiu.   

Abstract

OBJECTIVE: Accurate staging information is necessary to determine the prognosis of patients with hepatocellular carcinoma (HCC) and to guide subsequent patient management. This study aims to investigate the prognostic performance of the Hong Kong Liver Cancer (HKLC) classification in a Chinese cohort of HCC patients.
METHODS: A total of 668 HCC patients between 2003 and 2012 were included. Performances of the HKLC and the Barcelona Clinic Liver Cancer (BCLC) system were compared using Akaike information criterion (AIC), concordance-index (c-index), and area under the receiver operating characteristic curve (AUC). Independent prognostic factors of survival were identified using univariate and multivariate analyses.
RESULTS: Independent predictors of survival were Child-Pugh grade (P=0.009), lactate dehydrogenase (P<0.001) and albumin (P=0.001) levels, tumor location (P=0.032), tumor number (P<0.001), tumor size (P<0.001), and vascular invasion (P<0.001). Discriminatory ability was shown to be better for HKLC (AUC at 1, 3, and 5 years were 0.740, 0.695, and 0.615, respectively) than BCLC (AUC at 1, 3, and 5 years were 0.622, 0.569, and 0.548, respectively). On the basis of AIC and c-index, HKLC had a higher predictive power for survival (AIC=4709.480, c-index=0.805) than BCLC (AIC=4852.708, c-index=0.717).
CONCLUSION: In our selected patient population, whose main etiology was hepatitis B, the HKLC system was more suitable for predicting prognosis in a Chinese cohort of HCC patients than the BCLC classification.

Entities:  

Mesh:

Year:  2015        PMID: 26067223     DOI: 10.1097/MEG.0000000000000418

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  18 in total

1.  Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.

Authors:  Jae Ho Sohn; Rafael Duran; Yan Zhao; Florian Fleckenstein; Julius Chapiro; Sonia Sahu; Rüdiger E Schernthaner; Tianchen Qian; Howard Lee; Li Zhao; James Hamilton; Constantine Frangakis; MingDe Lin; Riad Salem; Jean-Francois Geschwind
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-12       Impact factor: 11.382

2.  The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable.

Authors:  Michael C Wallace; Matthew Knuiman; Yi Huang; George Garas; Leon A Adams; Gerry MacQuillan; David B Preen; Gary P Jeffrey
Journal:  Dig Dis Sci       Date:  2018-05-28       Impact factor: 3.199

3.  HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.

Authors:  Michael C Wallace; Yi Huang; David B Preen; George Garas; Leon A Adams; Gerry MacQuillan; Jonathan Tibballs; John Ferguson; Shaun Samuelson; Gary P Jeffrey
Journal:  Dig Dis Sci       Date:  2017-05-25       Impact factor: 3.199

4.  A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization.

Authors:  Ali Morshid; Khaled M Elsayes; Ahmed M Khalaf; Mohab M Elmohr; Justin Yu; Ahmed O Kaseb; Manal Hassan; Armeen Mahvash; Zhihui Wang; John D Hazle; David Fuentes
Journal:  Radiol Artif Intell       Date:  2019-09-25

Review 5.  Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.

Authors:  Fabio Piscaglia; Sadahisa Ogasawara
Journal:  Liver Cancer       Date:  2018-01-12       Impact factor: 11.740

6.  Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.

Authors:  Tom Tan-To Cheung; Philip Chong-Hei Kwok; Stephen Chan; Chin-Cheung Cheung; Ann-Shing Lee; Victor Lee; Hoi-Ching Cheng; Nam-Hung Chia; Charing C N Chong; Tak-Wing Lai; Ada L Y Law; Mai-Yee Luk; Chi Chung Tong; Thomas C C Yau
Journal:  Liver Cancer       Date:  2018-01-25       Impact factor: 11.740

7.  Anatomical sites (Takasaki's segmentation) predicts the recurrence-free survival of hepatocellular carcinoma.

Authors:  Wei Qin; Li Wang; Beiyuan Hu; Huan Tian; Cuicui Xiao; Huanxian Luo; Yang Yang
Journal:  BMC Surg       Date:  2021-06-03       Impact factor: 2.102

8.  Infiltrative Hepatocellular Carcinoma: Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy.

Authors:  Xiaopeng Yan; Xu Fu; Min Deng; Jun Chen; Jian He; Jiong Shi; Yudong Qiu
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 9.  Controversies and evidence of hepatic resection for hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Guido Torzilli; Hao Xing; Chao Li; Jun Han; Lei Liang; Han Zhang; Shu-Yang Dai; Le-Qun Li; Feng Shen; Tian Yang
Journal:  BBA Clin       Date:  2016-10-11

10.  Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma.

Authors:  Qing Pang; Jian-Bin Bi; Zhi-Xin Wang; Xin-Sen Xu; Kai Qu; Run-Chen Miao; Wei Chen; Yan-Yan Zhou; Chang Liu
Journal:  Onco Targets Ther       Date:  2016-04-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.